Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study
- Conditions
- Clinical Pharmacology, Healthy Male Volunteer Study
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 18
- Registration Number
- NCT02049528
- Locations
- 🇺🇸
Covance Clinical Development Services, Daytona Beach, Florida, United States
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1320
- Registration Number
- NCT02047734
- Locations
- 🇺🇸
Neurostudies Inc, Port Charlotte, Florida, United States
🇵🇱RESMEDICA Spolka z o.o., Kielce, Poland
🇵🇱Receptos Study Site 402, Olsztyn, Poland
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 81
- Registration Number
- NCT02045017
- Locations
- 🇮🇹
Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
🇬🇧Oxford Radcliffe Hospital ICRF Medical Oncology Unit, Headington, United Kingdom
🇫🇷CHU de Poitiers, Poitiers, France
3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 64
- Registration Number
- NCT02034773
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 174
- Registration Number
- NCT02031419
- Locations
- 🇮🇹
Local Institution - 201, Turin, Italy
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
- Conditions
- Squamous Cell Carcinoma, Non-Small-Cell Lung
- Interventions
- Other: Best Supportive Care (Maintenance)
- First Posted Date
- 2014-01-06
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 427
- Registration Number
- NCT02027428
- Locations
- 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸Hematology and Oncology Associates, Inc., Canton, Ohio, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT02021500
- Locations
- 🇦🇺
Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, Australia
🇫🇷Hôpital Beaujon, Clichy, France
🇺🇸Virginia Cancer Institute, Richmond, Virginia, United States
Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2017-09-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 83
- Registration Number
- NCT02017015
- Locations
- 🇨🇳
Xijing Hospital, Xi'an, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳307 Hospital of Chinese PLA, Beijing, China
Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2013-12-13
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT02011113
- Locations
- 🇯🇵
Celgene Trial Site, Tokyo, Japan
A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis
- Conditions
- AnemiaKidney Failure, Chronic
- Interventions
- Biological: Sotatercept
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 50
- Registration Number
- NCT01999582
- Locations
- 🇩🇪
KfH Kuratorium für Dialyse und Nierentransplantation e.v., München, Germany
🇵🇹Nephrocare Faro, Faro, Portugal
🇵🇹Hospital de Santa Maria, Lisboa, Portugal